Protein S deficiency and novel oral anticoagulants: An intriguing case by Tàssies, Dolors & García de Frutos, Pablo
Protein S deficiency and novel oral anticoagulants: an intriguing case 
Dolors Tàssies (1) and Pablo García de Frutos (2) 
1 Department of Hemotherapy and Hemostasis, Hospital Clinic, Institut d'Investigacions 
Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, 
Catalonia, Spain. 
2 Institute of Biomedical Research of Barcelona, IIBB-CSIC, IDIBAPS, Barcelona, 
Spain.  
Vitamin K- dependent protein S (ProS) is a plasma glycoprotein with anticoagulant 
properties [1]. Its anticoagulant function is well established in the literature based both 
in clinical data, genetics and laboratory assays. ProS is able to prolong the clotting time 
acting as cofactor for activated protein C. Furthermore, since the 80s it is known that 
hereditary ProS deficiency (PSD) increases the risk of venous thrombosis in families 
with hereditary thrombophilia [2], later found to be mostly caused by mutations in its 
coding gene, PROS1. Indeed, mutations in PROS1 have been shown to confer more 
than 7-fold risk of thrombosis in selected families with PSD [3]. The recent 
establishment of mice strains with mutations in Pros1 has emphasized the importance 
of ProS as a pleiotropic anticoagulant in vivo [4, 5]. 
Nevertheless, although the view of ProS as an essential natural anticoagulant is well-
grounded, we could consider that ProS is one of the components of the coagulation 
cascade that has brought more surprising discoveries in recent years. The seminal 
work by Dahlbäck demonstrating that ProS interacted with high affinity with the 
complement regulator C4b-binding protein (C4BP) and that a high molecular weight 1:1 
ProS-C4BP complex was present in human plasma [6], was an early basis for the 
concept of hemostasis and inflammation as parts of a global response to damage, 
which has led to the present concept of thrombo-inflammation [7]. The C4BP-ProS 
complex has implications in PSD, which has been classified in three categories: type I 
corresponding to concentrations of total ProS antigen below the normal range 
(quantitative deficiency), type II being normal levels of a ProS with low activity 
(qualitative deficiency) and type III corresponding to a specific quantitative deficiency of 
free, uncomplexed ProS in plasma despite levels of total ProS antigen inside the 
normal range [1,8]. 
More recently, the discovery of ProS and GAS6 as ligands of receptor tyrosine kinases 
and the discovery of its growth-factor like properties have brought new functional 
horizons to ProS, including its important implication in apoptotic cell removal 
(efferocytosis) and “taming” of inflammatory reactions [4, 8, 9]. Its role as anticoagulant 
has also been revised by the suggestion of new mechanisms, including the binding and 
effect of Zn2+ ions [11] and the ProS-dependent inhibition of factor Xa by TFPI [12]. 
From this studies, an antithrombotic activity of ProS that is independent of the action on 
activated protein C has been proposed and corroborated by in vivo studies in mice [4] 
and primates [13]. 
The study of the molecular basis of PSD has also provided some surprises. Studies of 
thrombophilia in different geographical areas have found that the incidence and type of 
PSD is very heterogeneous among populations [14]. In families with hereditary PSD 
where the traditional sequence technology failed to find a causative mutation, the use 
of new genetic screening techniques have discovered a relatively high frequency of 
small and large deletions in or close to the PROS1 locus [15,16]. Finally, relatively mild 
polymorphism in PROS1 could manifest as causative mutations in combination with 
other thrombophilic factors, especially in combination with the FV Leiden mutation, 
suggesting that there could be possible mechanisms of prothrombotic synergy among 
common genetic variants [17,18]. 
In this context, the study by Wypasek et al. presents an interesting observation. The 
authors describe two families with severe familiar PSD due to a non-sense mutation 
and an insertion leading to a frame shift mutation. Both mutations predict truncated 
protein products. In both probands, plasma free ProS levels are very low, below 20% 
although in one case the total ProS level was inside the reference range, and should 
be considered a type III deficiency.  
Both cases were treated with the new oral anticoagulant rivaroxaban, a selective direct 
factor Xa inhibitor. Interestingly, in both patients, thrombotic complications occurred 
under rivaroxaban therapy at two and five months of treatment respectively, and in 
consequence the antithrombotic therapy had to be modified. This observation could 
suggest that rivaroxaban is less effective for the treatment of thrombosis in patients 
with severe PSD. Nevertheless, the authors state that in their clinical experience with 
mild PSD patients (ie above 30% free ProS level) or in cases of protein C deficiency, 
the clinical response to rivaroxaban was similar to that observed in patients without 
thrombophilia. 
At present, there are no large studies on the efficacy of each novel oral anticoagulant 
depending on specific causes of thrombophilia. Still, it is important to have in mind that 
the new oral anticoagulants interact with one specific target in the coagulation cascade 
(factor Xa for rivaroxaban), as opposed to the anti-vitamin K oral anticoagulants or 
heparins that interact with several coagulation factors. In principle, different genetic 
causes of thrombophilia could affect differently the effect of these drugs. 
 In the cases reported by Wypasek et al., one could speculate that the very low ProS 
concentration eliminates the natural inhibitory mechanism controlling factor Xa through 
TFPI. This could be aggravated by the fact that PSD patients show also decreased 
plasma concentration of TFPI [18]. Overall, these could result in less control of the 
factor Xa activity generated in severe PSD patients compared to patients with a 
different protrombotic origin. 
Although it could now seem far-fetched, the combined knowledge on the specific 
causes of thrombophilia, their mechanisms of action, and how these mechanisms 
interact with different antithrombotic drugs could lead to personalized treatments that 
would be more efficient.  
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